Stock Movers Novo Nordisk Falls, Praxis Precision Rallies, Lululemon Rises
Dec 29, 2025
Novo Nordisk has slashed the price of its obesity drug Wegovy in China, preparing for increased competition. Praxis Precision has received FDA breakthrough therapy designation for its essential tremor treatment, boosting its stock. Meanwhile, Chip Wilson, the founder of Lululemon, is pushing for board changes as the company faces challenges in leadership and doubts over its ambitious sales targets for 2026. Tensions are rising at Lululemon as it navigates these critical transitions.
AI Snips
Chapters
Transcript
Episode notes
Novo Nordisk Lowers China Prices
- Novo Nordisk cut Wegovy list prices in parts of China ahead of expected copycats and patent expiry.
- The move signals pricing pressure as GLP-1 competition heats up and the company readies for generics.
GLP-1 Race Reshapes Winners
- GLP-1 drugs remain the key battleground with Novo Nordisk and Eli Lilly diverging this year.
- Novo Nordisk is down ~40% YTD while Eli Lilly is up ~40% as competition reshapes market leadership.
Praxis Gains From Breakthrough Tag
- Praxis Precision jumped after FDA granted breakthrough therapy designation for ulixacaltamide for essential tremor.
- Analysts view this as a major catalyst positioning Praxis for potential strong 2026 results.